Discover more insights into First Generation Egfr Tki

Keywords frequently search together with First Generation Egfr Tki

Narrow sentence examples with built-in keyword filters

First Generation Egfr Tki sentence examples within progression free survival



Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations



Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations.



Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib As First-Line Treatment For Advanced Non-Small-Cell Lung Cancer With EGFR Sensitizing Mutation (CATLA-2): A Study Protocol For A Double-Blind Randomized Controlled Trial


More First Generation Egfr Tki sentence examples
10.1016/j.critrevonc.2021.103393

Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.



Cytoplasmic P120ctn Promotes Gefitinib Resistance in Lung Cancer Cells by Activating PAK1 and ERK Pathway.


More First Generation Egfr Tki sentence examples
10.1200/JCO.2021.39.15_SUPPL.2028

The efficacy and clinical survival outcome of different first-line treatments in EGFR-mutant non-small cell lung cancer with brain metastases.



Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma



Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients



Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy



Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation


More First Generation Egfr Tki sentence examples
10.1200/JCO.2021.39.15_SUPPL.E21074

Identification of RET fusion as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.



The Role of De Novo T790M Mutation in The Origin of T790M Resistance Clone and in The Clinical Outcomes For Advanced EGFR-Mutant NSCLC Patients Receiving EGFR-TKIs



Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations



Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs



Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial



Icotinib, an Effective Treatment Option for Patients With Lung Adenocarcinoma Harboring Compound EGFR L858R and A871G Mutation



Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer



Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis



Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC


More First Generation Egfr Tki sentence examples
10.1200/JCO.2021.39.15_SUPPL.9030

The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.



Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis.



The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study



Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer



Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation



The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study



First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials



Abstract 377: Molecular features-based model for predicting benefit from Bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor



Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy



Clinical Outcomes of Patients Taking First-generation EGFR-TKIs May Predict the Benefits Afforded by Osimertinib in EGFR T790M-mutant NSCLC Patients.



Improving outcomes for brain metastases in EGFR mutated NSCLC.


More First Generation Egfr Tki sentence examples
10.1200/JCO.2019.37.15_SUPPL.9083

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.



DIAGNOSTIC ACCURACY OF L1 HOUNSFIELD UNIT METHOD COMPARED TO QCT IN DETECTING OSTEOPOROSIS IN A LUNG CANCER SCREENING COHORT



DIAGNOSTIC TEST OF CANCER RATIO EXAMINATION OF MALIGNANT PLEURAL EFFUSION PATIENTS AT PERSAHABATAN HOSPITAL JAKARTA


Learn more from First Generation Egfr Tki


First Generation Egfr Tki
Encyclopedia